Literature DB >> 6108221

Haemodynamic effects, plasma concentrations and tolerance of orally administered prenalterol in man.

A Weiss, B Pfister, P Imhof, P H Degen, D Burckhardt, U C Dubach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6108221     DOI： 10.1007/bf00636789

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  18 in total

1.  Simplified method for the determination of oxprenolol and other beta-receptor-blocking agents in biological fluids by gas-liquid chromatography.

Authors:  P H Degen; W Riess
Journal:  J Chromatogr       Date:  1976-06-09

2.  Human pharmacology studies with a new, orally active stimulant of cardiac adrenergic beta-receptors.

Authors:  M Knaus; B Pfister; U C Dubach; P R Imhof
Journal:  Am Heart J       Date:  1978-05       Impact factor: 4.749

Review 3.  Symposium on vasodilator and inotropic therapy of heart failure. Symposium perspective.

Authors:  D T Mason
Journal:  Am J Med       Date:  1978-07       Impact factor: 4.965

4.  Bedside technics for the evaluation of ventricular function in man.

Authors:  A M Weissler; W S Harris; C D Schoenfeld
Journal:  Am J Cardiol       Date:  1969-04       Impact factor: 2.778

5.  [Therapy of orthostatic circulatory disorders].

Authors:  R Gotzen
Journal:  Ther Ggw       Date:  1978-08

6.  Cardiovascular effects of prenalterol (H133/22) in normal man.

Authors:  D H Scott; G R Arthur; R N Boyes; D B Scott
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

7.  Haemodynamic effects of a new beta 1-receptor agonist in acute myocardial infarction. A useful antidote to unwanted cardiac effects of beta-blocking agents.

Authors:  R Ariniego; F Waagstein; B Mombay; A Hjalmarson
Journal:  Br Heart J       Date:  1979-08

8.  [Diagnosis and therapy of arterial hypotension].

Authors:  P Imhof; B Garnier
Journal:  Praxis       Date:  1965-12-09

9.  Selection of vasodilator, inotropic or combined therapy for the management of heart failure.

Authors:  J N Cohn; J A Franciosa
Journal:  Am J Med       Date:  1978-07       Impact factor: 4.965

10.  Metabolic and haemodynamic effects and pharmacokinetics of a new selective beta 1-adrenoceptor agonist, prenalterol, in man.

Authors:  O Rönn; E Fellenius; C Graffner; G Johnsson; P Lundborg; L Svensson
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953
View more
  6 in total

1.  Pharmacokinetics of prenalterol after single and multiple administration of controlled release tablets to patients with congestive heart failure.

Authors:  U Dahlström; C Graffner; U Jonsson; K J Hoffmann; E Karlsson; P O Lagerström
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Pharmacokinetics and plasma-concentration-effect relationships of prenalterol in cardiac failure.

Authors:  E J Sainsbury; D Fitzpatrick; H Ikram; M G Nicholls; E A Espiner; J J Ashley
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Effect of prenalterol in asthmatic patients.

Authors:  C G Löfdahl; N Svedmyr
Journal:  Eur J Clin Pharmacol       Date:  1982-10       Impact factor: 2.953

4.  Short- and long-term effects of hydralazine and combined hydralazine-prenalterol therapy in severe chronic congestive heart failure.

Authors:  H Drexler; H Löllgen; H Just
Journal:  Klin Wochenschr       Date:  1981-06-15

5.  Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure.

Authors:  P J Currie; M J Kelly; K Middlebrook; J Federman; E Sainsbury; J Ashley; A Pitt
Journal:  Br Heart J       Date:  1984-05

Review 6.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.